ArticleThe New England journal of medicine2016
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia; Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia; Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia.
Article in The New England journal of medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
CD19-CAR-T2 Cells for Relapse/Refractory CD19 Positive Acute Leukemia-a Phase I Trial
The Effect of CAR-T Cell Therapy on the Reconstitution of HIV-specific Immune Function
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers.Molecules (Basel, Switzerland) · 2021Pooled it
- Prognostic factor analysis of CD19 CAR-T therapy followed by hematopoietic stem cell transplantation in relapsed/refractory B-ALL.Clinical and experimental medicine · 2026Article
- A Tetrameric Biotin-Avidin Scaffold Using Anti-CD19 (FMC63) Traptavidin Fusion Enables High-Avidity CAR-T Cells for Leukemia Therapy.Bioconjugate chemistry · 2026Article
- Leveraging T cells for cancer immunotherapy.Immunity & inflammation · 2025Review
- Long-term complete response to anti-programmed-death-1 monotherapy in a patient with relapsed and refractory ovarian adenocarcinoma: A case report.World journal of clinical cases · 2024Article
- Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T.Molecular cancer · 2023Review
- Conformation-selective rather than avidity-based binding to tumor associated antigen derived peptide-MHC enables targeting of WT1-pMHC low expressing cancer cells by anti-WT1-pMHC/CD3 T cell engagers.Frontiers in immunology · 2023Article
- Emerging Trends in Immunotherapy for Cancer.Diseases (Basel, Switzerland) · 2022Review
- Immunotherapies and Renal Injury.Current opinion in toxicology · 2022Article
- Reforming the Chimeric Antigen Receptor by Peptide Towards Optimized CAR T Cells With Enhanced Anti-Cancer Potency and Safety.Frontiers in bioengineering and biotechnology · 2022Article
- Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies.BMC cancer · 2021Article
- A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma.Frontiers in oncology · 2021Article
- A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma.OncoTargets and therapy · 2021Review
- Lack of tocilizumab effect on mortality in COVID19 patients.Scientific reports · 2020Article
- Aberrant expression and regulatory network of splicing factor-SRSF3 in tumors.Journal of Cancer · 2020Review
- The killing effect of novel bi-specific Trop2/PD-L1 CAR-T cell targeted gastric cancer.American journal of cancer research · 2019Article
- Neurological complications of new chemotherapy agents.Neuro-oncology · 2018Article
- Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients.Journal of hematology & oncology · 2018Article
- Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies.Cancer letters · 2017Review
- Genetically engineered T cells for cancer immunotherapy.Signal transduction and targeted therapyReview
Corrections and comments
- Erratum for
- Erratum for
- Erratum for
Authors and funding
0 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
26962747What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.